Elizabeth Spoljoric
Women's Health · la Porte, INNPI 1457057341
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.
Across 49 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exeltis, USA Inc.$170
- Agile Therapeutics, Inc.$165
- AbbVie$96
- Astellas Pharma US Inc$87
- Bayer$81
- Shield Therapeutics Inc$79
- plus $290 from 13 others
What the payments were for
- Food & beverage$968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exeltis, USA Inc. | 9 | $170 |
| Agile Therapeutics, Inc. | 7 | $165 |
| AbbVie | 6 | $96 |
| Astellas Pharma US Inc | 5 | $87 |
| Bayer | 4 | $81 |
| Shield Therapeutics Inc | 2 | $79 |
| Biogen | 2 | $47 |
| Tris Pharma Inc | 2 | $40 |
| Vertex | 2 | $37 |
| Exact Sciences | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Dexcom, Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Corium, LLC | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Merck | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Organon | 1 | $9 |
How this compares
$968 in reported general payments places this provider in the 75th percentile of 142 women's health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 58 | $3,283 |
| IntrarosaPrasterone (Dhea) | 11 | $2,999 |
| ProgesteroneProgesterone, Micronized | 13 | $489 |
| Gabapentin | 13 | $356 |
| Nystatin | 14 | $181 |
| Clobetasol Propionate | 18 | $153 |
Paid to pharmacies, not to this prescriber.
Other women's health in la Porte
- Cara RaunickIndianapolis$73K
- Debra TaylorGreenwood$33K
- Elizabeth FourmanNotre Dame$15K
- Amanda NakashianDyer$8K
- Courtney CortezIndianapolis$5K
- Natasha StruewingGreensburg$5K
- Rebecca PapamihalakisMunster$4K
- Kesha KellyIndianapolis$4K
- Amanda PhelpsEvansville$4K
- Taylor JohnsonNoblesville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.